secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001193125-23-273532
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Pharma Q3 net loss widens to $33.1M; cash at $595.1M; pipeline milestones on track
--------------------------------------------------------------------------------

- Net loss of $33.1M ($0.40/share) vs $8.1M ($0.10) a year ago, driven by R&D spending surge to $28.2M.
- Cash, cash equivalents and marketable securities $595.1M at Sept 30, down $13M from June 30.
- Phase 3 SUNRISE-3 for bemnifosbuvir in COVID-19 enrollment ongoing; first interim analysis expected Q1 2024.
- Phase 2 HCV combination trial (bemnifosbuvir + ruzasvir) lead-in cohort fully enrolled; initial data also due Q1 2024.
- Interest income rose to $7.9M from $4.4M on higher yields; total operating expenses $40.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/0001193125-23-273532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523273532/d524760d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-273532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer